Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428019
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-20
Brief Title:
A Study to Evaluate the Risk of Tumor Lysis Syndrome TLS in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia CLL
Sponsor:
AbbVie
Organization:
AbbVie